- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07919860
Observation Study on the Efficacy and Safety of Hepatic Artery Embolization Combined With Radiofrequency Ablation for Hepatic Hemangioma: The Impact of Different Treatment Intervals
The goal of this observational study is to learn about the efficacy-safety profiles of combined hepatic arterial embolization (TAE) and laparoscopic radiofrequency ablation (RFA) in patients with hepatic hemangioma who receive sequential TAE-RFA treatment. The main question it aims to answer is: Does the time interval between TAE and subsequent RFA influence therapeutic efficacy and safety in patients with hepatic hemangioma receiving sequential TAE-RFA therapy? Participants already undergoing TAE followed by RFA as part of their regular clinical management for hepatic hemangioma will undergo scheduled laboratory tests and contrast-enhanced abdominal CT examinations over a 12-month follow-up period.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Ying Xing
- Phone Number: +86 13552079962
- Email: xingying@bjtth.org
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Patients aged 18-80 years with hepatic hemangioma >5 cm, eligible for transarterial embolization (TAE), and with acceptable liver function reserve. Patients with contrast allergy or anesthesia contraindications are excluded. Enrolled participants are stratified into two cohorts according to the time interval between TAE and subsequent laparoscopic radiofrequency ablation (RFA): short-interval group (10-14 days after TAE) and long-interval group (2-3 months after TAE).
Description
Inclusion Criteria: Age 18-80 years; definite HH diagnosis via abdominal imaging with diameter > 5 cm; identifiable feeding artery suitable for embolization; preserved hepatic reserve without severe pre-existing liver disease; no contrast media allergy; no surgical anesthesia contraindications; subjects understand procedural risks and are willing for study participation.
- Exclusion Criteria: Uncertain HH diagnosis where other solid hepatic lesions cannot be excluded; hepatic insufficiency, liver cirrhosis, ascites, hepatic encephalopathy; concurrent active anti malignant tumor therapy for hepatic or extra hepatic neoplasms; contrast media allergy or severe cardiopulmonary cerebrovascular diseases precluding procedural tolerance; pregnant or lactating women, patients with pregnancy planning requirements; refusal of study participation after adequate information disclosure.
-
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Short-interval group
RFA is performed at 10-14 days after TAE |
Right femoral artery access; embolic agents: gelatin sponge particles combined with lipiodol; procedural endpoint: cessation of lipiodol inflow into hemangioma lesion Laparoscopic radiofrequency ablation to facilitate intra operative bleeding surveillance and ablation zone assessment. Hepatic inflow occlusion will be performed for lesions >10 cm |
|
Long-interval group
RFA is performed at 2-3 months after TAE |
Right femoral artery access; embolic agents: gelatin sponge particles combined with lipiodol; procedural endpoint: cessation of lipiodol inflow into hemangioma lesion Laparoscopic radiofrequency ablation to facilitate intra operative bleeding surveillance and ablation zone assessment. Hepatic inflow occlusion will be performed for lesions >10 cm |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Tumour volume reduction rate
Time Frame: 6 month and 12 month post RFA
|
6 month and 12 month post RFA
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Peri-procedural complication incidence
Time Frame: day 1 post TAE and day 1 / day 4 post RFA
|
day 1 post TAE and day 1 / day 4 post RFA
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BTHospitalPW
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.